Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant + nab-paclitaxel in platinum-resistant ovarian cancer
NCT03776812Phase 2Completed
- Sponsor
- Corcept Therapeutics
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of relacorilant in ovarian cancer, fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC) (3 arms), sponsored by Corcept Therapeutics. Primary endpoint: Progression-Free Survival at 15 months. Started Apr 2019; status: completed.
02
Drugs
relacorilant
03
Conditions
ovarian cancerfallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03776812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776812.